semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 24.0-35.0,  Osteoporosis Healthy Caucasian subjects of both sexes between the ages of 24-35 years -  Pregnancy Subjects with cardiac, hypertension, vascular, renal, pulmonary, endocrine, musculoskeletal, hepatic hematologic or malignant or rheumatologic disease. Body Mass Index greater than 30 anemia (hematocrit less than 36% in women, less than 40% in men) significant alcohol or drug abuse, baseline hypotension (systolic blood pressure less than 90 mm/HG) baseline hypertension (systolic BP greater than 140 mmHg or diastolic BP greater than 90 mmHg Abnormal screening labs including: ionized and total serum calcium, phosphorus, creatinine, albumin, 25-hydroxyvitamin D, and PTH. Subjects taking any chronic medication except oral contraceptives Those who have received an investigational drug in the past 90 days Any subject who has previously received either PTH or PTHrP African Americans and other ethnic minorities will be excluded since it is well documented that osteoporosis is far more common in Caucasians than in African-Americans, and there are clear quantitative differences in bone density and sensitivity to parathyroid hormone between African-Americans and Caucasians. -
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Aging Healthy volunteers age 18 and over  Significant abnormalities on health history questionnaire or in the results of blood tests Pregnant or nursing mother Participation in another research study within the past six weeks that is felt by the Principal Investigator to be incompatible with this study Severe infection in the past two months Immune disorder, or use of any medication that can alter immune system function A medical or mental health finding showing inability to go through the procedure Body mass index (BMI) greater than 29% Chronic back pain, sciatica, or a compression fracture of the spine Positive test results for viral infections: Hepatitis B, Hepatitis C, or HIV (AIDS)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 5.0-999.0,  Hypophosphatemic Rickets, X-Linked Dominant Established patients with XLH Age 5 years old and above Normal serum calcium and creatinine concentrations  Patients with hypersensitivity to any component(s) of cinacalcet Hypocalcaemia Elevated serum creatinine
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Osteoporosis Osteoporosis, Postmenopausal Women Caucasian Hispanic Asian One year past onset of menopause Weigh between 50 and 90 kilograms  Taking bisphosphonates in the last 2 years Estrogen replacement hormones in last year SERMS in last year One weeks worth of PTHrP, PTH or an analog of PTH in past year Recent non-traumatic bone fracture within last year Significant uncontrolled cardiac, vascular, renal, pulmonary, endocrine or rheumatologic disease History of malignancy Anemia Significant alcohol or drug abuse Receiving any investigational drug within past 90 days
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fibromyalgia meet from primary FMS as defined by the ACR: widespread aching pain in all four quadrants of the body and axial skeleton and greater than or equal to 11 of 18 tender points under digital palpation examination measure average pain item of the BPI at Visits 1 and 2  have pain symptoms related to traumatic injury, structural rheumatic disease, or regional rheumatic disease that will interfere with interpretation of outcome measures have regional pain syndrome, multiple surgeries or failed back syndrome have confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an autoimmune disease (i.e. systemic lupus erythematosus) have current primary Axis I diagnosis other than major depressive disorder (MDD), including a current diagnosis of dysthymia
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-99.0,  Congenital Adrenal Hyperplasia (CAH) Familial Male-Limited Precocious Puberty (FMPP) Males, ages 0 with known or suspected FMPP or 2. Patients (males and females, ages 0 with known or suspected (based on hormonal, clinical and/or genetic testing) CAH of any type. 3. Patients with excess androgen of unknown etiology or 4. Relatives of patients in this protocol  Females with isolated polycystic ovary syndrome. If, following a diagnostic work-up, a patient is determined to have PCOS as the only cause of her hyperandrogenism; she will no longer be followed on this protocol. 2. Patients with significant non-endocrine medical conditions. 3. Females who are pregnant at the time of initial enrollment
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasms Women with a diagnosis of hormone receptor positive invasive breast cancer (Stage I-IIIB) or ductal carcinoma in situ (DCIS) Postmenopausal status Completed at least 8 weeks of anastrozole as adjuvant therapy prior to study entry Completed systemic chemotherapy and radiation treatments when indicated Serum Calcium ≤ 10.3 mg/dL Patients with marginal 25 OH Vitamin D level (between 10 and 29 ng/ml) will be in the Randomized Group or Low 25 OH Vitamin D level (less than 10 ng/ml) will be in Observational Group hour urine Calcium excretion ≤ 250 mg/g (calculated by dividing 24 hour calcium by 24 hour creatinine) A history of generalized musculoskeletal pain with or without localized regions or discomfort that has developed or worsened since starting adjuvant aromatase inhibitor therapy  Known metastatic disease History of kidney stones History of active primary hyperparathyroidism History of Paget's disease of the bone History of severe arthritis, rheumatoid arthritis, or severe neuropathy Normal 25 OH Vitamin D level (≥ 30 ng/ml) Medical or psychiatric condition which may preclude protocol compliance
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Leukemia Myelodysplastic Syndromes Diagnosis of one of the following hematologic malignancies Myelodysplastic syndromes (MDS) of one of the following French-American-British (FAB) classifications Refractory anemia with excess blasts (RAEB) (WHO RAEB-1) RAEB in transformation (RAEB-t) (RAEB-2) Chronic myelomonocytic leukemia (CMML) with > 5% myeloblasts (WHO CMML-2) International Prognostic Scoring System (IPSS) score of intermediate-2 or higher in the setting of > 5% myeloblasts Acute myeloid leukemia that has evolved from MDS Must not be a candidate for bone marrow transplantation as first-line therapy or must have declined bone marrow transplantation Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Life expectancy of at least 4 months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Pain Patient is 18 through 70 years of age Patient has moderate to severe non-malignant chronic pain Patient is opioid-tolerant, requires treatment with chronic opioids and is currently taking a dose of 50 mcg/hr transdermal fentanyl for the treatment of chronic pain. Patient must have been taking this dose for at least 2 weeks Patient must be experiencing 1 to 4 episodes of target breakthrough pain (breakthrough pain that is related to the patient's chronic pain condition) a day while taking a dose of 50 mcg/hr transdermal fentanyl  Patient has active cancer Patient has a history of substance abuse or has a substance abuse disorder Patient is pregnant or breastfeeding
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin B12 Deficiency Patients suspected to have vitamin B12 deficiency defined as a plasma vitamin B12 below the reference interval (<200 pmol/L)  Patients who were pregnant, nursing or not able to give written informed consent were excluded
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-82.0,  Renal Osteodystrophy age 18 years old or older, male or female able to sign informed consent CKD stage 3 (GFR 30-59 ml/min) or stage 4 (15-29 ml/min) intact Parathyroid hormone level (iPTH) > 100 pg/ml for stage 3 or iPTH > 150 pg/ml for stage 4 calcidiol levels ≤ 20 ng/ml ability to ambulate without assistance  intact PTH > 400 pg/ml initial corrected Calcium > 9.7 mg/dl initial serum Phosphorous > 5.0 mg/dl initial standardized blood pressure of > 160/100 history of significant liver disease or cirrhosis anticipated requirement for dialysis in 6 months malabsorption, severe chronic diarrhea, or ileostomy no calcimimetic or active vitamin D therapy 30 days prior to enrollment use of digoxin, magnesium containing products, mineral oil, or cholestyramine
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-75.0,  Osteoarthritis Rheumatoid Arthritis Post-traumatic Arthritis Avascular Necrosis Acute Fracture Primary total hip replacement Patient age less than or equal to 75 Sufficient bone stock to support prosthesis  Previous hip replacement Significant angular/bony deformity Active joint sepsis Metal allergy Renal transplant Psychosocial disease Neurological disease/musculoskeletal disease that may affect weight-bearing
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Early Breast Cancer Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole WHO performance status 0, 1 or 2 Provision of written informed consent  Recurrence of breast cancer, inflammatory rheumatism treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin Diabetes treated by insulin Severe renal or hepatic disease Known hypersensitivity to anastrozole
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Secondary Hyperparathyroidism Chronic Kidney Disease Inclusion:≥ 18 years of age Treated with maintenance hemodialysis PTH ≥ 300 pg/mL (31.8 pmol/L) serum calcium ≥ 8.4mg/dL (2.1 mmol/L) Ca x P ≥ 45 mg2*/dL2 (3.63 mmol2/L2)  Parathyroidectomy in the 12 weeks before the date of informed consent Received therapy with cinacalcet within 3 months of randomization Hospitalization within 12 weeks of randomization for any of the following events: a. Myocardial ischemia b. Unstable angina c. Heart Failure (HF) (including any unplanned presentation to a health care facility that would require mechanical intervention [i.e., unplanned dialysis treatment]) d. Peripheral vascular disease (other than dialysis vascular access revision) e. Stroke History of seizure within 12 weeks prior to randomization Scheduled date for kidney transplant from a known living donor Anticipated parathyroidectomy within 6 months after randomization in all instances, the 2 refers to squared
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypoparathyroidism Adult hypoparathyroid patients, as defined by low or inappropriately normal PTH levels despite hypocalcemia, who are on a stable treatment regimen of calcitriol and calcium supplementation, and who are willing to participate in the study will be eligible. Adult PHP1B patients as defined by the clinical syndrome of elevated PTH and phosphorus and confirmed by methylation analysis of the GNAS gene  Renal insufficiency as evidenced by a creatinine clearance of less than 50 ml/min Medically unstable patients Uncontrolled comorbid conditions, e.g., diabetes, coronary artery disease, congestive heart failure, or cerebrovascular disease. Digitalis therapy Patients on diuretic therapy, especially thiazides Pregnant and lactating women Patients whose hypoparathyroidism is caused by severe calcium-sensing receptor defects. These patients begin to have marked symptoms of "hypercalcemia" when the serum calcium is in the mid-normal range. Patients under 18 years of age Patients with history of any bone cancer, skeletal metastases or previous radiotherapy to the skeleton, unexplained elevations of serum alkaline phosphatase
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Myelodysplastic Syndromes Pathologically confirmed myelodysplastic syndromes (MDS), including any of the following Refractory anemia (RA) RA with ringed sideroblasts Refractory cytopenias with multilineage dysplasia (RCMD) RCMD with ringed sideroblasts RA with excess blasts 1 (5-9% blasts) RA with excess blasts 2 (10-19% blasts) Must have poor-risk MDS, defined by the following At least 2 lineages involved Unfavorable cytogenetics (i.e., abnormalities of chromosome 5 or 7, 11q23, t[6;9], trisomy 8, inv3, or multiple/complex karyotype)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 24.0-35.0,  Osteoporosis Bone Diseases, Endocrine Hyperparathyroidism Healthy Caucasian, Hispanic or Asian subjects Males and Females Non-smoker Ages 24 years old Subjects will be recruited either from the employee pool of the University of Pittsburgh or the University of Pittsburgh Medical Center (UPMC), or the general population living in the vicinity Participation in this study by an employee or a potential employee at the University of Pittsburgh or UPMC has no effect on their employment or potential employment Participants in the study will be required to discontinue all vitamins and health food supplements two weeks prior to the study  Cardiac, hypertensive, vascular, renal (serum creatinine of >1.5), pulmonary, endocrine, musculoskeletal, hepatic, hematologic or malignant or rheumatologic disease Body Mass Index (BMI) > 30 Anemia (hematocrit less than 36% in women, less than 40% in men) Pregnancy (all women will have a urine pregnancy test performed immediately before starting the study and must not be pregnant) Significant alcohol or drug abuse or Baseline hypotension (systolic blood pressure less than 90 mm/Hg) Subjects will be excluded for abnormal levels of any of the screening labs including: ionized and total serum calcium, phosphorus, creatinine, albumin, 25-hydroxyvitamin D, and PTH. Pregnancy Subjects taking any chronic medications except oral contraceptives and stable doses of thyroid hormone, or those who have received any investigational drug in past 90 days will be excluded from the study Subjects may not participate in this study more than once Any subject who has previously received PTH or PTHrP, a related peptide, may not participate in this study. Minority Inclusion/Exclusion Statement: We will not African-Americans because this group has been demonstrated by a number of investigators to display resistance to PTH, and may create wider statistical variation and a need for larger numbers of study subjects per group
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.096,  Vitamin D Deficiency Healthy singleton term born infants of appropriate size for gestational age (AGA) according to the Centers for Disease Control growth charts based on weight at birth between the 5th and 95th percentiles for sex; and born to healthy breastfeeding women. This allows us to assess growth and bone mineral accretion without bias of intrauterine growth restriction  Infants of mothers with history of gestational diabetes or hypertension in pregnancy; chronic alcohol use; malabsorption syndromes due to malabsorption of vitamin D (celiac disease, Crohn's etc.); and multiple births Should any be identified after recruitment, the infant will be excluded from the main analyzes, but followed in a separate arm as intent-to-treat
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Fibromyalgia Meets American College of Rheumatology (ACR) for FM Inactive at study entry Willing to become more physically active Understands and willing to follow study recommendations regarding lifestyle modification Able to participate in the study for 2 years Agrees to not make any changes to current FM-related treatments  Any comorbidity that may worsen a participant's physical functioning, independent of FM (e.g., significant cardiovascular disease, history of arrhythmias, morbid obesity, autoimmune diseases, uncontrolled or untreated hypertension, significant renal or prostate disease, stroke, seizure disorder, any other significant neurological diseases) Significant peripheral neuropathy Any current psychiatric disorder that involves a history of psychosis, including schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, bipolar disorder, or severe personality disorder. Participants with mood disorder are not excluded Alcohol or substance abuse within the 2 years prior to study entry Current suicide risk or suicide attempt within the 2 years prior to study entry Severe physical disability that may interfere with physical activity Currently participates in structured exercise or plans to participate in an exercise program Any investigational medications or devices within 4 weeks prior to study entry Any expected life change, such as relocation, within the next 2 years that may prevent study participation